JP2014513951A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513951A5 JP2014513951A5 JP2014506553A JP2014506553A JP2014513951A5 JP 2014513951 A5 JP2014513951 A5 JP 2014513951A5 JP 2014506553 A JP2014506553 A JP 2014506553A JP 2014506553 A JP2014506553 A JP 2014506553A JP 2014513951 A5 JP2014513951 A5 JP 2014513951A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- acid sequence
- amino acid
- endoglin polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000012085 Endoglin Human genes 0.000 claims 1
- 108010036395 Endoglin Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477585P | 2011-04-20 | 2011-04-20 | |
| US61/477,585 | 2011-04-20 | ||
| PCT/US2012/034295 WO2012145539A1 (en) | 2011-04-20 | 2012-04-19 | Endoglin polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017224413A Division JP6803315B2 (ja) | 2011-04-20 | 2017-11-22 | エンドグリンポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513951A JP2014513951A (ja) | 2014-06-19 |
| JP2014513951A5 true JP2014513951A5 (enExample) | 2015-06-18 |
| JP6250533B2 JP6250533B2 (ja) | 2017-12-20 |
Family
ID=46000405
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506553A Expired - Fee Related JP6250533B2 (ja) | 2011-04-20 | 2012-04-19 | エンドグリンポリペプチドおよびその使用 |
| JP2017224413A Expired - Fee Related JP6803315B2 (ja) | 2011-04-20 | 2017-11-22 | エンドグリンポリペプチドおよびその使用 |
| JP2020134862A Active JP7097930B2 (ja) | 2011-04-20 | 2020-08-07 | エンドグリンポリペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017224413A Expired - Fee Related JP6803315B2 (ja) | 2011-04-20 | 2017-11-22 | エンドグリンポリペプチドおよびその使用 |
| JP2020134862A Active JP7097930B2 (ja) | 2011-04-20 | 2020-08-07 | エンドグリンポリペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9932386B2 (enExample) |
| EP (2) | EP3549952A1 (enExample) |
| JP (3) | JP6250533B2 (enExample) |
| CN (3) | CN108178789B (enExample) |
| AU (4) | AU2012245439B2 (enExample) |
| CA (1) | CA2833747C (enExample) |
| DK (1) | DK2699590T3 (enExample) |
| WO (1) | WO2012145539A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| CA2833747C (en) | 2011-04-20 | 2022-10-18 | Asya Grinberg | Endoglin polypeptides and uses thereof |
| EP2739645B1 (en) * | 2011-08-01 | 2018-12-19 | Tufts Medical Center, Inc. | Endoglin-specific antibody for use in a method of treating heart failure and related conditions |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| US10214590B2 (en) | 2013-09-20 | 2019-02-26 | Tufts Medical Center, Inc. | Inhibitors of endoglin activity for the treatment of fibrosis |
| EP3060235B1 (en) * | 2013-10-25 | 2020-12-02 | Acceleron Pharma Inc. | Endoglin peptides to treat fibrotic diseases |
| EP4417255A3 (en) | 2013-11-21 | 2024-10-23 | The Brigham and Women's Hospital Inc. | Compositions and methods for treating pulmonary hypertension |
| DK3122375T3 (da) | 2014-03-28 | 2021-05-25 | Univ Washington Through Its Center For Commercialization | Vacciner mod bryst- og ovariecancer |
| GB201412290D0 (en) | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| WO2016019368A1 (en) | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| EP4218792A1 (en) | 2015-08-04 | 2023-08-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| CN110452295B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物 |
| WO2017176938A1 (en) * | 2016-04-06 | 2017-10-12 | Acceleron Pharma, Inc. | Bmprii polypeptides and uses thereof |
| CA3029890A1 (en) * | 2016-07-07 | 2018-01-11 | Acceleron Pharma Inc. | Tgf-beta superfamily heteromultimers and uses thereof |
| DK3628049T3 (da) | 2017-05-04 | 2023-08-14 | Acceleron Pharma Inc | Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf |
| EP3735418A4 (en) * | 2018-01-03 | 2021-11-10 | Acceleron Pharma Inc. | ONE-ARMED CO-RECEPTOR FUSION PROTEINS AND USES THEREOF |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| US20220195500A1 (en) * | 2019-04-26 | 2022-06-23 | Vanderbilt University | Probes for detecting rna and methods of use thereof |
| US20220195056A1 (en) * | 2019-08-07 | 2022-06-23 | Icahn School Of Medicine At Mount Sinai | Method of treating keloids |
| EP4081240A4 (en) * | 2019-12-03 | 2023-12-06 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONARY HYPERTENSION |
| WO2021167952A2 (en) * | 2020-02-20 | 2021-08-26 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
| KR20220021207A (ko) * | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| US20220233714A1 (en) * | 2021-01-27 | 2022-07-28 | Vanderbilt University | Nanogold-dna bioconjugates and methods of use thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| CZ291047B6 (cs) | 1992-10-28 | 2002-12-11 | Genentech, Inc. | Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| CA2147754A1 (en) * | 1992-10-30 | 1994-05-11 | Michelle Letarte | Compositions and methods for modifying the regulatory activity of tgf- .beta. |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| MX9701946A (es) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| KR100856995B1 (ko) | 1997-04-07 | 2008-09-04 | 제넨테크, 인크. | 인간화 항체 및 인간화 항체의 제조 방법 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| MEP13708A (en) | 2000-06-23 | 2010-06-10 | Bayer Schering Pharma Ag | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| PL1638941T3 (pl) | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
| RS20181002A1 (sr) | 2003-05-30 | 2018-12-31 | Genentech Inc | Tretman sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| WO2007143023A1 (en) * | 2006-05-31 | 2007-12-13 | Beth Israel Deaconess Medical Center | Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer |
| ES2612755T3 (es) * | 2006-11-02 | 2017-05-18 | Acceleron Pharma, Inc. | Antagonistas de receptor y ligando de ALK1 y usos de los mismos |
| WO2008151078A1 (en) | 2007-06-01 | 2008-12-11 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| US20100210713A1 (en) | 2009-01-16 | 2010-08-19 | The General Hospital Corporation | Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor |
| CN102548617B (zh) * | 2009-03-30 | 2017-11-07 | 阿塞勒隆制药公司 | Bmp‑alk3拮抗剂和促进骨生长的用途 |
| US20120183543A1 (en) | 2009-05-08 | 2012-07-19 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
| US8795663B2 (en) * | 2010-01-12 | 2014-08-05 | Beth Israel Deaconess Medical Center, Inc. | Soluble endoglin and uses thereof |
| CA2833747C (en) | 2011-04-20 | 2022-10-18 | Asya Grinberg | Endoglin polypeptides and uses thereof |
| EP2739645B1 (en) | 2011-08-01 | 2018-12-19 | Tufts Medical Center, Inc. | Endoglin-specific antibody for use in a method of treating heart failure and related conditions |
| US10214590B2 (en) | 2013-09-20 | 2019-02-26 | Tufts Medical Center, Inc. | Inhibitors of endoglin activity for the treatment of fibrosis |
| EP3060235B1 (en) | 2013-10-25 | 2020-12-02 | Acceleron Pharma Inc. | Endoglin peptides to treat fibrotic diseases |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
-
2012
- 2012-04-19 CA CA2833747A patent/CA2833747C/en active Active
- 2012-04-19 CN CN201810139884.7A patent/CN108178789B/zh not_active Expired - Fee Related
- 2012-04-19 CN CN201810139885.1A patent/CN108341863A/zh active Pending
- 2012-04-19 DK DK12717013.2T patent/DK2699590T3/en active
- 2012-04-19 JP JP2014506553A patent/JP6250533B2/ja not_active Expired - Fee Related
- 2012-04-19 AU AU2012245439A patent/AU2012245439B2/en not_active Ceased
- 2012-04-19 US US14/112,620 patent/US9932386B2/en active Active
- 2012-04-19 CN CN201280030070.0A patent/CN103781798B/zh not_active Expired - Fee Related
- 2012-04-19 EP EP19150039.6A patent/EP3549952A1/en active Pending
- 2012-04-19 EP EP12717013.2A patent/EP2699590B8/en active Active
- 2012-04-19 WO PCT/US2012/034295 patent/WO2012145539A1/en not_active Ceased
-
2017
- 2017-03-13 AU AU2017201711A patent/AU2017201711B2/en not_active Ceased
- 2017-11-22 JP JP2017224413A patent/JP6803315B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-28 US US15/908,644 patent/US10981972B2/en active Active
-
2019
- 2019-07-11 AU AU2019204979A patent/AU2019204979B2/en not_active Ceased
-
2020
- 2020-08-07 JP JP2020134862A patent/JP7097930B2/ja active Active
- 2020-09-30 AU AU2020244456A patent/AU2020244456A1/en not_active Abandoned
-
2021
- 2021-03-18 US US17/205,573 patent/US20210300991A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513951A5 (enExample) | ||
| JP2013172734A5 (enExample) | ||
| JP2011155981A5 (enExample) | ||
| JP2013523703A5 (enExample) | ||
| IL281648A (en) | Solid forms of }[5-(3-chlorophenyl)-3-hydroxypyridi-2-carbonyl]amino{ acetic acid, their compositions and uses | |
| JP2011136997A5 (enExample) | ||
| HUE062740T2 (hu) | GLP-1 peptidek készítményei és elõállításuk | |
| JP2014132019A5 (enExample) | ||
| ZA201308251B (en) | Amino acid sequence presenting fusion polypeptide and its use | |
| EP2822923A4 (en) | PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND THEIR ESTERS | |
| JP2015038108A5 (enExample) | ||
| JP2011136981A5 (enExample) | ||
| HUE054444T2 (hu) | Prolinnal lezárt kapcsos peptidek és felhasználásuk | |
| JP2012126742A5 (enExample) | ||
| EP2874642A4 (en) | Anti-inflammatory proteins and peptides, and methods for their preparation and use | |
| SG11201503052RA (en) | Disubstituted amino acids and methods of preparation and use thereof | |
| JP2014503607A5 (enExample) | ||
| UA118167C2 (uk) | Пептид та його застосування | |
| IL229539A0 (en) | Hyaluronic acid-binding synthetic peptidoglycans, prepartion, and methods of use | |
| BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática | |
| GB201315335D0 (en) | Amino diacids containing peptide modifiers | |
| JP2015533791A5 (enExample) | ||
| JP2010265269A5 (enExample) | ||
| AP2015008948A0 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| PH12016500101A1 (en) | Protease-resistant peptide ligands |